Boomi Unveils Comprehensive API Management to Combat API Sprawl and Power Agentic AI
Boomi™, the intelligent integration and automation leader, today unveiled its comprehensive API Management (APIM) solution, delivering cloud-scale APIM alongside market-leading integration and automation, data management, and AI capabilities as part of the Boomi Enterprise Platform. Comprised of Boomi’s existing API Management offering along with assets recently acquired from both Cloud Software Group and APIIDA, Boomi API Management enables enterprises to conquer API chaos, power agentic AI, and unleash their business potential – transforming APIs into strategic drivers of growth.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218487717/en/
Boomi Unveils Comprehensive API Management to Combat API Sprawl and Power Agentic AI (Graphic: Business Wire)
According to IDC, organizations with GenAI enhanced applications/services in production have roughly five times more APIs than organizations not yet investing significantly in GenAI1. Without proper management, the resulting ‘API sprawl’ can overwhelm teams, create chaos, and introduce security risks. As APIs fuel the AI Era by enabling seamless data access, system integration, and autonomous decision-making, Boomi API Management plays a critical role in addressing API sprawl by enhancing discoverability, security, and scalability – helping businesses unlock the transformative potential of AI while adapting to evolving user personas and demands.
“APIs have become the backbone of AI-driven innovation, enabling seamless interaction between AI models, agents, and enterprise systems," said Shari Lava, Senior Research Director, AI and Automation at IDC. "Effective API management is no longer optional — it is critical for organizations to ensure security, scalability, and governance while reducing complexity and API sprawl. Without a robust APIM strategy, businesses risk losing control over their AI initiatives and missing out on their full transformative potential."
Boomi API Management is a flexible, holistic solution with support for Boomi and third-party API gateways. The offering, powered by Boomi AI Agents, helps enterprises close security gaps, tackle API sprawl, and transform technology investments into a competitive advantage. Unlike API Management point solutions, Boomi API Management is part of the Boomi Enterprise Platform, which brings together market-leading capabilities for integration and automation, data management, and AI management to deliver unmatched performance and business value in a single platform.
According to Sebastiaan Kalshoven, CTO of De Volksbank, "Boomi provides De Volksbank's management and IT teams with transparency across the entire API landscape of different runtime vendors. It scans all APIs and creates the security and quality score to strengthen API governance and enables the implementation of different dev portals for internal and external use. It brings together technical and business stakeholders and provides a clear view on the realized business value.”
Key capabilities of Boomi API Management
Fortify Governance for all APIs: Transform data, applications, and AI assets into secure, scalable APIs that fuel innovation while safeguarding critical information. Unify and govern APIs to eliminate shadow APIs, boost quality and reusability, and enable AI-ready workflows.
Scale Infinitely in the Cloud: Power mission-critical applications and AI with elastic scalability that delivers superior performance and reliability. Enable seamless collaboration and speed to meet the demands of diverse personas and dynamic business needs.
Connect Everything on one Platform: Fuel revenue growth and accelerate outcomes by connecting APIs, applications, data, and AI on a single platform. Gain real-time insights and unlock new possibilities with AI-driven experiences, enhanced efficiency, and lower costs.
"APIs underpin the global digital economy and play a vital role in the AI Era — managing them effectively is crucial for success," said Ed Macosky, Chief Product and Technology Officer, Boomi. "Boomi API Management unlocks the full potential of APIs, accelerating growth and digital transformation. By uniting industry-leading integration, automation, and data management, Boomi sets a new standard for API management and AI innovation — helping organizations achieve business outcomes faster."
Read our blog post “The State of API Management: Challenges and Opportunities” to learn more about how Boomi API Management can help organizations navigate the complexities of modern API ecosystems.
Additional Resources
- Explore the Boomiverse Community
- Follow Boomi on X (Twitter), LinkedIn, Facebook, and YouTube
About Boomi
Boomi, the intelligent integration and automation leader, helps organizations around the world automate and streamline critical processes to achieve business outcomes faster. Harnessing advanced AI capabilities, the Boomi Enterprise Platform seamlessly connects systems and manages data flows with API management, integration, data management, and AI orchestration in one comprehensive solution. With over 23,000 customers globally and a rapidly expanding network of 800+ partners, Boomi is revolutionizing the way enterprises of all sizes achieve business agility and operational excellence. Discover more at boomi.com.
© 2025 Boomi, LP. Boomi, the ‘B’ logo, and Boomiverse are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.
1 IDC, API Sprawl and AI Enablement: API Management Results from AI-Enhanced Connectivity Survey, 2024, doc #US52736424, December 2024
View source version on businesswire.com: https://www.businesswire.com/news/home/20250218487717/en/
Contacts
Boomi Media Contact:
Kristen Walker
Global Corporate Communications
kristenwalker@boomi.com
+1-415-613-8320
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Microba Announces Landmark GI Study Results From Over 4,600 Patients15.5.2025 05:12:00 EEST | Press release
Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”), a precision microbiome company, today announces preliminary results from the analysis of over 4,600 MetaXplore™ GI Plus test results, a comprehensive test for the assessment and management of lower gastrointestinal disorders, spanning symptoms including chronic pain, bloating, constipation, or diarrhea. This study demonstrates that MetaXplore can support clinicians to identify and address underlying gut issues that often go undetected by conventional testing. In over 70% of cases, the test revealed findings, such as abnormalities in gut bacteria, signs of infection, markers of inflammation or insufficiency that could inform targeted treatment strategies. Further, two-thirds of MetaXplore patients in a separate study of follow up survey results reported improvement of symptoms after their care was guided by the test results. This press release features multimedia. View the full release here: https://www.businesswire.
Bloomstreet Enters into Strategic Partnership Agreement with Google Israel for Market Expansion in Japan15.5.2025 05:00:00 EEST | Press release
Bloomstreet Inc. (Headquarters: Chuo-ku, Tokyo; President & CEO: Junichi Takayama; hereinafter “Bloomstreet”), a company that supports overseas enterprises entering the Japanese market, is pleased to announce a strategic partnership agreement with Google Israel Ltd. (Headquarters: Tel Aviv District; Country Manager: Barak Regev; hereinafter “Google Israel”). This partnership aims to support Israeli companies that operate globally with Google Ads and are seeking to expand into the Japanese market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250514387485/en/ How do Bloomstreet and Google Israel collaborate? The partnership between Bloomstreet and Google Israel is designed to support Israeli companies seeking to expand into the Japanese market by optimizing their website UI/UX, thereby enhancing the effectiveness of their Google Ads campaigns. Background of the Partnership Known as a "Start-up Nation," Israel is home to many
Rubedo Life Sciences’ Drug Discovery Platform, ALEMBIC™, Helps Identify Senescent or “Zombie” Neurons in New Study Linking Neuropathic Pain and Aging Published in Peer-Reviewed Scientific Journal Nature Neuroscience15.5.2025 04:11:00 EEST | Press release
Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that using open source codes integrated in the company’s broader propriety drug discovery platform, ALEMBIC™, helped to identify senescent neurons in a new study that found senescent neurons drive chronic pain with injury and age.1 Senescent cells, often called “zombie” cells, arise as the results of cellular stress and damage. These senescent cells do not die but undergo cellular changes, including secreting pro-inflammatory factors, thereby potentially contributing to inflammatory responses within the body.1 The study, led by Stanford University scientists, Vivianne Tawfik, MD, PhD, and Lauren Donovan, PhD, and co-authored by Rubedo team members, including Chief Scientific Officer Marco Quarta, PhD, and Chief Technology Officer Alex Laslavic, was published in the May 14th edition of Nat
The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 115.5.2025 00:03:00 EEST | Press release
Takeda (TSE: 4502/NYSE:TAK) today announced that the New England Journal of Medicine published data from the Phase 2b trial of oveporexton (TAK-861) in people with narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to restore orexin signaling to address the underlying orexin deficiency that causes NT1. Results demonstrated significant improvement in objective and subjective measures of excessive daytime sleepiness (EDS), reductions in cataplexy events and clinically meaningful improvements in disease severity and quality of life across all doses tested compared to placebo through eight weeks of treatment. NT1 is a severe, chronic neurological condition caused by a significant loss of orexin-producing neurons, resulting in low levels of orexin leading to EDS, cataplexy (sudden loss of muscle tone), cognitive symptoms, disrupted nighttime sleep, hallucinations that occur as one falls asleep or wakes up and sleep paralysis.T
BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation14.5.2025 23:05:00 EEST | Press release
BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will share data across a range of hematologic malignancies at the European Hematology Association (EHA) Congress in Milan, Italy, June 12–15. BeiGene has 31 abstracts accepted at EHA 2025, with four selected for oral presentations, featuring data from its best-in-class Bruton’s tyrosine kinase (BTK) inhibitor BRUKINSA® (zanubrutinib) and its investigational pipeline assets – a next-generation BCL2 inhibitor, sonrotoclax, and BTK protein degrader, BGB-16673. These data reflect BeiGene’s vision to redefine standards of care in hematology through next-generation science and patient-focused innovation. “With three cornerstone hematology assets – BRUKINSA, sonrotoclax and BGB-16673 – we are advancing a potentially best-in-class portfolio in B-cell malignancies,” said Lai Wang, Ph.D. Global Head of R&D. “At EHA 2025, we’ll share 31 accepted ab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom